NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 365 filers reported holding NEKTAR THERAPEUTICS in Q1 2018. The put-call ratio across all filers is 0.43 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $15,000 | -48.3% | 735 | -40.5% | 0.00% | -60.0% |
| Q2 2020 | $29,000 | +31.8% | 1,235 | 0.0% | 0.01% | +11.1% |
| Q1 2020 | $22,000 | +46.7% | 1,235 | +75.2% | 0.01% | +80.0% |
| Q4 2019 | $15,000 | +15.4% | 705 | 0.0% | 0.01% | 0.0% |
| Q3 2019 | $13,000 | -80.0% | 705 | -61.6% | 0.01% | -79.2% |
| Q2 2019 | $65,000 | +3.2% | 1,835 | -2.3% | 0.02% | -7.7% |
| Q1 2019 | $63,000 | -37.0% | 1,879 | -38.2% | 0.03% | -50.0% |
| Q4 2018 | $100,000 | -47.1% | 3,039 | -1.8% | 0.05% | -40.2% |
| Q3 2018 | $189,000 | +29.5% | 3,095 | +3.3% | 0.09% | +7.4% |
| Q2 2018 | $146,000 | -52.3% | 2,995 | +3.8% | 0.08% | -55.2% |
| Q1 2018 | $306,000 | +106.8% | 2,884 | +16.0% | 0.18% | +70.8% |
| Q4 2017 | $148,000 | – | 2,486 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
| First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
| BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
| Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
| BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
| Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
| Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
| Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
| TOBAM | 640,547 | $21,522,000 | 1.09% |
| Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |